488 related articles for article (PubMed ID: 30980360)
1. Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37.
Wang G; Narayana JL; Mishra B; Zhang Y; Wang F; Wang C; Zarena D; Lushnikova T; Wang X
Adv Exp Med Biol; 2019; 1117():215-240. PubMed ID: 30980360
[TBL] [Abstract][Full Text] [Related]
2. Modulation of antimicrobial potency of human cathelicidin peptides against the ESKAPE pathogens and in vivo efficacy in a murine catheter-associated biofilm model.
Narayana JL; Mishra B; Lushnikova T; Golla RM; Wang G
Biochim Biophys Acta Biomembr; 2019 Sep; 1861(9):1592-1602. PubMed ID: 31319057
[TBL] [Abstract][Full Text] [Related]
3. Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37.
Lakshmaiah Narayana J; Golla R; Mishra B; Wang X; Lushnikova T; Zhang Y; Verma A; Kumar V; Xie J; Wang G
ACS Infect Dis; 2021 Jun; 7(6):1795-1808. PubMed ID: 33890759
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific Regulation of Innate Immune Responses by Human Cathelicidin LL-37.
Chieosilapatham P; Ikeda S; Ogawa H; Niyonsaba F
Curr Pharm Des; 2018; 24(10):1079-1091. PubMed ID: 29589544
[TBL] [Abstract][Full Text] [Related]
5. High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.
Wang G; Mishra B; Epand RF; Epand RM
Biochim Biophys Acta; 2014 Sep; 1838(9):2160-72. PubMed ID: 24463069
[TBL] [Abstract][Full Text] [Related]
6. 17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeae.
Lee SG; Kiattiburut W; Khongkha T; Schinkel SCB; Lunn Y; Decker AP; Mohammadi A; Vera-Cruz A; Misra A; Angel JB; Anderson DJ; Baker M; Kaul R; Wang G; Tanphaichitr N
Hum Reprod; 2022 Oct; 37(11):2503-2517. PubMed ID: 36053257
[TBL] [Abstract][Full Text] [Related]
7. Peptide Stability Is Important but Not a General Requirement for Antimicrobial and Antibiofilm Activity In Vitro and In Vivo.
Decker AP; Su Y; Mishra B; Verma A; Lushnikova T; Xie J; Wang G
Mol Pharm; 2023 Jan; 20(1):738-749. PubMed ID: 36485036
[TBL] [Abstract][Full Text] [Related]
8. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections.
Méndez-Samperio P
Peptides; 2010 Sep; 31(9):1791-8. PubMed ID: 20600427
[TBL] [Abstract][Full Text] [Related]
9. Unique features of human cathelicidin LL-37.
Bandurska K; Berdowska A; Barczyńska-Felusiak R; Krupa P
Biofactors; 2015; 41(5):289-300. PubMed ID: 26434733
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella.
Amer LS; Bishop BM; van Hoek ML
Biochem Biophys Res Commun; 2010 May; 396(2):246-51. PubMed ID: 20399752
[TBL] [Abstract][Full Text] [Related]
11. Transformation of human cathelicidin LL-37 into selective, stable, and potent antimicrobial compounds.
Wang G; Hanke ML; Mishra B; Lushnikova T; Heim CE; Chittezham Thomas V; Bayles KW; Kielian T
ACS Chem Biol; 2014 Sep; 9(9):1997-2002. PubMed ID: 25061850
[TBL] [Abstract][Full Text] [Related]
12. Synergistic microbicidal effect of cationic antimicrobial peptides and teicoplanin against planktonic and biofilm-encased Staphylococcus aureus.
Koppen BC; Mulder PPG; de Boer L; Riool M; Drijfhout JW; Zaat SAJ
Int J Antimicrob Agents; 2019 Feb; 53(2):143-151. PubMed ID: 30315918
[TBL] [Abstract][Full Text] [Related]
13. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity.
Fabisiak A; Murawska N; Fichna J
Pharmacol Rep; 2016 Aug; 68(4):802-8. PubMed ID: 27117377
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence.
Zaiou M; Nizet V; Gallo RL
J Invest Dermatol; 2003 May; 120(5):810-6. PubMed ID: 12713586
[TBL] [Abstract][Full Text] [Related]
15. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities.
Braff MH; Hawkins MA; Di Nardo A; Lopez-Garcia B; Howell MD; Wong C; Lin K; Streib JE; Dorschner R; Leung DY; Gallo RL
J Immunol; 2005 Apr; 174(7):4271-8. PubMed ID: 15778390
[TBL] [Abstract][Full Text] [Related]
16. Membrane Core-Specific Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofibre Formation.
Shahmiri M; Enciso M; Adda CG; Smith BJ; Perugini MA; Mechler A
Sci Rep; 2016 Nov; 6():38184. PubMed ID: 27901075
[TBL] [Abstract][Full Text] [Related]
17. Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding.
Yu J; Dai Y; Fu Y; Wang K; Yang Y; Li M; Xu W; Wei L
Antiviral Res; 2021 Mar; 187():105021. PubMed ID: 33508330
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Antimicrobial Screening Sensitivity Enabled the Identification of an Ultrashort Peptide KR-8 for Engineering of LL-37mini to Combat Drug-Resistant Pathogens.
Mechesso AF; Su Y; Xie J; Wang G
ACS Infect Dis; 2023 Nov; 9(11):2215-2225. PubMed ID: 37812567
[TBL] [Abstract][Full Text] [Related]
19. LL-37 fragments have antimicrobial activity against Staphylococcus epidermidis biofilms and wound healing potential in HaCaT cell line.
Saporito P; Vang Mouritzen M; Løbner-Olesen A; Jenssen H
J Pept Sci; 2018 Jul; 24(7):e3080. PubMed ID: 29737589
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of human cathelicidin LL-37 by free fatty acids and their analogs.
Jiang W; Sunkara LT; Zeng X; Deng Z; Myers SM; Zhang G
Peptides; 2013 Dec; 50():129-38. PubMed ID: 24140860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
